<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26794">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968915</url>
  </required_header>
  <id_info>
    <org_study_id>CLCL161A1102</org_study_id>
    <nct_id>NCT01968915</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceutical and Medical Devices Agency (PMDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety and tolerability to estimate the maximum tolerated dose
      and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of dose limiting toxicities as a function of LCL161 during first cycle</measure>
    <time_frame>First cycle (21 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of oral LCL161</measure>
    <time_frame>From informed consent until 28 days after end of treatment (end of treatment visit occurs within 7 days after the determination of study discontinuation)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type and frequency of adverse events of oral LCL161 when administered in combination with weekly paclitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of oral LCL161</measure>
    <time_frame>From informed consent until 28 days after end of treatment (end of treatment visit occurs within 7 days after the determination of study discontinuation)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type and frequency of adverse events of oral LCL161</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCL161 plasma concentration and derived pharmacokinetic parameters</measure>
    <time_frame>From first cycle and up to 3 cycle (each cycle is 21-day period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paclitaxel plasma concentration and derived pharmacokinetic parameters</measure>
    <time_frame>From first cycle of combination and up to 2 cycle (each cycle is 21-day period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to RECIST 1.1</measure>
    <time_frame>Every 2 cycles for first 8 cycles, then every 3 cycles and until end of treatment (each cycle is 21-day period and end of treatment visit occurs within 7 days after the determination of study discontinuation)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCL161</intervention_name>
    <description>Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.</description>
    <arm_group_label>LCL161</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.</description>
    <arm_group_label>LCL161</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with a histologically or cytologically confirmed diagnosis of a solid tumor
             for which no further effective standard treatment is available.

          2. ECOG performance status 0-1.

          3. Patients must have recovered from all toxicities related to their previous treatment.

        Exclusion criteria:

          1. Unresolved nausea, vomiting, diarrhea or peripheral neuropathy CTCAE grade &gt;1.

          2. History of or current interstitial lung disease or autoimmune disease.

          3. History of or current impaired cardiac function or clinically significant cardiac
             diseases.

          4. Women of child-bearing potential, unless they are using highly effective methods of
             contraception.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCL161, Paclitaxel, Japanese patient, Neoplasms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
